Sam Brusco, Associate Editor03.15.21
Baxter obtained Food and Drug Administration (FDA) clearance for its next-generation Artificial Kidney 98 (AK 98) dialysis machine, a portable and easy-to-use system to administer hemodialysis (HD) treatments. AK 98 features encrypted, two-way connectivity, enabling the system to pull prescriptions directly from the electronic medical record.
“We designed this latest version of our AK 98 system to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sessions per machine per day,” Gavin Campbell, general manager of Baxter’s U.S. Renal Care business told the press. “With our recent De Novo authorization of Theranova, our novel dialysis membrane, our latest innovations to support HD provide our customers with choices for therapy and treatment modality.”
Due to kidney failure, people with end-stage renal disease retain harmful toxins in their blood. AK 98 offers several key features to help dialysis providers efficiently manage HD treatment sessions across chronic dialysis and hospital care environments, including:
AK 98 builds on Baxter’s longstanding tradition of pioneering and delivering groundbreaking advancements in the HD space. It’s currently used in over 90 countries and will be available in the U.S. in the coming weeks.
“We designed this latest version of our AK 98 system to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sessions per machine per day,” Gavin Campbell, general manager of Baxter’s U.S. Renal Care business told the press. “With our recent De Novo authorization of Theranova, our novel dialysis membrane, our latest innovations to support HD provide our customers with choices for therapy and treatment modality.”
Due to kidney failure, people with end-stage renal disease retain harmful toxins in their blood. AK 98 offers several key features to help dialysis providers efficiently manage HD treatment sessions across chronic dialysis and hospital care environments, including:
- Automatic Alert Resolution, which enables the machine to self-clear already corrected pressure alarms and avoid unnecessary stoppage of treatment due to brief pressure fluctuations often related to patient movement. This helps streamline patient management by limiting direct exposure and number of redundant device interventions.
- An intuitive, customizable user interface with app-like functionality designed to simplify prescription management and treatment supervision.
- A fast, simple set-up process that can be completed by a technician or nurse, allowing for greater flexibility and utilization of staff time and resources.
- A stable base design that allows for easy concentrate or portable reverse osmosis storage and transport with the machine.
AK 98 builds on Baxter’s longstanding tradition of pioneering and delivering groundbreaking advancements in the HD space. It’s currently used in over 90 countries and will be available in the U.S. in the coming weeks.
